Scancell Holdings Plc

Scancell Holdings Plc

1.15
USD
-0.03
(-2.54%)
177.50MMarket Cap
Feb 04Next Earn
Scancell Holdings Plc
OTC:SCNLD
(OTC Markets)

Recent

price

1.15

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
GBP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.06
- -
0.05
- -
- -
Revenue per Share
-0.01
- -
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
-0.23
-0.06
-0.15
-0.07
-0.13
-0.17
- -
Basic EPS, GAAP
-0.01
- -
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
-0.02
-0.01
-0.13
-0.14
-0.1
-0.18
-0.08
-0.1
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.03
0.03
0.03
0.04
0.03
0.04
0.02
0.04
0.02
0.02
0.11
0.02
-0.12
-0.04
-0.04
-0.19
-0.19
Book Value per Share
0.01
0.02
0.01
0.02
0.01
0.02
0.01
0.03
0.01
0.01
0.06
-0.02
-0.16
-0.04
-0.05
-0.2
-0.2
Tangible Book Value per Share
164
191
200
223
231
233
268
320
395
466
68
82
82
86
97
104
104
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
5
- -
5
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-226.14
- -
-318.42
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
1
1
- -
Depreciation Expense
-2
1
-2
-2
-2
-3
-4
-4
-6
-6
-15
-5
-12
-6
-12
-18
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-226.45
- -
-260.5
- -
- -
Profit Margin (%)
1
3
2
6
3
7
3
10
6
4
42
26
17
15
-6
-21
-21
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
15
17
18
18
- -
- -
- -
LT Debt
5
7
5
9
7
10
6
14
9
8
9
1
-10
-4
-4
-19
-19
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
-30.87
9.6
-31.53
-31.38
-30.5
-30.85
-42.99
-41.04
-48.35
-64.83
-189.48
-90.64
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

GBP

•

in mil. unless spec.
Apr'25
Oct'26
Apr'26
ST Debt
16
16
17
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
104
104
104
Market Capitalization
132
93
130

Working Capital

GBP

•

in mil. unless spec.
Apr'25
Oct'26
Apr'26
Total Current Assets
21
13
8
Cash, Cash Equivalents & STI
17
9
5
Accounts Receivable, Net
- -
1
- -
Inventories
- -
- -
- -
Total Current Liabilities
27
24
30
Payables & Accruals
- -
- -
- -
ST Debt
16
16
17
Deferred Revenue
- -
- -
- -

Growth Rates

GBP

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-48.21%
-104.84%
406.13%
Free Cash Flow
27.48%
16.77%
37.01%
Net Income, GAAP
46.38%
39.04%
45.87%
Sales/Revenue/Turnover
- -
- -
-100%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
5
2026
- -
- -
- -

Semi-annual Earnings Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.07
2025
- -
- -
-0.13
2026
- -
- -
-0.17

Semi-annual Dividends Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -
Business
Scancell Holdings plc (LSE:SCLP) is a clinical-stage biopharmaceutical company that develops novel immunotherapies targeting cancer through proprietary platforms including ImmunoBody and Moditope for vaccines; GlyMab and AvidiMab for monoclonal antibodies. ImmunoBody vaccines, such as SCIB1, iSCIB1+, SCIB2, SC129 and SC134, stimulate CD4 and CD8 T-cell responses against tumor-specific peptides to induce potent, durable anti-tumor immunity in solid tumors including metastatic melanoma; Moditope vaccines, such as Modi-1 and Modi-2, target citrullinated and homocitrullinated peptides to harness T-cell responses against a broad range of solid tumors; GlyMab antibodies, including SC2811 and SC27, enhance antibody-dependent cellular cytotoxicity by modifying glycan structures on monoclonal antibodies; AvidiMab enhances antibody potency through molecular modifications. The company, founded in 1996 and headquartered at Bellhouse Building, Oxford Science Park, Oxford, England, operates primarily in the United Kingdom with a pipeline focused on unmet needs in oncology across multiple solid tumor indications. Recent developments include a partnership with the NHS Cancer Vaccine Launchpad for fast-tracked access to SCOPE trials in melanoma patients; a strategic alliance with PharmaJet for the Stratis needle-free injectable device in iSCIB1+ studies; a second commercial license agreement with Genmab yielding $6 million upfront and potential milestones of $630 million plus royalties, validating the GlyMab platform; incorporation of GlyMab Therapeutics Limited as a wholly-owned subsidiary in June 2025; and accelerated plans for randomized registration studies of iSCIB1+ starting in 2026 following Phase 2 data.

Company News

  • Scancell revs up for Nasdaq listing as cancer vaccine developer prepares phase III melanoma trial

  • Scancell (LON:SCLP) Share Price Crosses Below 200-Day Moving Average – Here’s Why

  • Scancell Holdings secures $25m financing as it advances melanoma trial

  • Cancer vaccine breakthrough at Moderna raises hopes for Scancell's melanoma programme

  • Marvell shares jump as Google warrant deepens AI chip partnership

  • Scancell secures UK clearance for late-stage melanoma trial

  • Ford and GM upgraded by Jefferies on improving outlooks, stronger cash generation

  • Chip stocks slide as China advances domestic lithography, memory production

  • Scancell sees high demand in retail share offer, seals £15.7m from UK investors

  • SMALL-CAP MOVERS: Nasdaq-bound Scancell catches the eye as AIM's headcount falls to 612

  • American Airlines shares fall as fuel costs weigh on third-quarter outlook despite earnings beat

  • Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing

  • Scancell to join Nasdaq through Neuphoria merger and $89 million funding package

  • Scancell to join Nasdaq through Neuphoria merger and $89 million funding package

  • Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc

  • Scancell confirms advanced talks over reverse merger with Neuphoria

  • Scancell's melanoma data keeps widening the gap over standard care as phase III funding race heats up

  • Scancell's melanoma data keeps widening the gap over standard care as phase III funding race heats up

  • Scancell wins FDA fast-track status for melanoma immunotherapy

  • Scancell receives FDA Fast Track Designation for iSCIB1+ in advanced melanoma and provides data update from its SCOPE Phase 2 study